Scarica l'app Stockscreener
24.84
1.23%
-0.31
Dopo l'orario di chiusura:
25.15
0.31
+1.25%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CPRX Giù?
Forum
Previsione
Precedente Chiudi:
$25.15
Aprire:
$25.08
Volume 24 ore:
953.03K
Relative Volume:
0.80
Capitalizzazione di mercato:
$3.02B
Reddito:
$460.48M
Utile/perdita netta:
$142.80M
Rapporto P/E:
21.05
EPS:
1.18
Flusso di cassa netto:
$221.79M
1 W Prestazione:
+7.25%
1M Prestazione:
+14.68%
6M Prestazione:
+26.99%
1 anno Prestazione:
+52.67%
Intervallo 1D:
$24.64
$25.40
Intervallo di 1 settimana:
$23.17
$26.16
Portata 52W:
$14.47
$26.16
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Nome
Catalyst Pharmaceuticals Inc
Settore
Industria
Telefono
(305) 529-2522
Indirizzo
355 ALHAMBRA CIRCLE, CORAL GABLES
Confronta CPRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
24.84 | 3.02B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.55 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
635.83 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
593.47 | 36.20B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.02 | 35.08B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
262.60 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-03-14 | Iniziato | Citigroup | Buy |
| 2024-03-07 | Iniziato | BofA Securities | Buy |
| 2023-12-21 | Iniziato | Oppenheimer | Outperform |
| 2022-08-24 | Downgrade | ROTH Capital | Buy → Neutral |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Ripresa | Piper Jaffray | Overweight |
| 2016-10-05 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | Reiterato | ROTH Capital | Buy |
| 2014-09-16 | Reiterato | ROTH Capital | Buy |
| 2014-09-15 | Reiterato | H.C. Wainwright | Buy |
| 2013-10-21 | Reiterato | Aegis Capital | Buy |
| 2013-09-24 | Iniziato | Maxim Group | Buy |
| 2013-09-06 | Reiterato | Aegis Capital | Buy |
| 2013-04-18 | Iniziato | Aegis Capital | Buy |
| 2012-08-27 | Aggiornamento | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | Aggiornamento | Merriman | Sell → Neutral |
| 2009-05-29 | Downgrade | Hapoalim | Neutral → Underperform |
| 2009-05-29 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | Iniziato | Merriman Curhan Ford | Buy |
| 2007-11-28 | Iniziato | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | Iniziato | Stifel Nicolaus | Buy |
| 2007-01-05 | Iniziato | First Albany | Buy |
Mostra tutto
Catalyst Pharmaceuticals Inc Borsa (CPRX) Ultime notizie
Jim Cramer on Catalyst Pharmaceuticals (CPRX): ‘That’s My Kind of Stock!’ - Insider Monkey
With 81% ownership in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), institutional investors have a lot riding on the business - Yahoo Finance
Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains? - Yahoo Finance
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) large institutional owners must be happy as stock continues to impress, up 18% over the past week - Simply Wall St
Santhera to share latest on commercial rollout of AGAMREE® and future strategic priorities at Capital Markets Day - GlobeNewswire Inc.
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Bank of New York Mellon Corp Raises Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Catalyst Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
Proficio Capital Partners LLC Makes New $339,000 Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Catalyst Pharmaceuticals: Undervalued Future With Multiple Upside Catalysts - Seeking Alpha
Catalyst Pharmaceuticals Inc (CPRX) Q4 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
Gary Ingenito Sells 44,904 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock - Defense World
Where are the Opportunities in (CPRX) - Stock Traders Daily
Catalyst Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Executive VP & Chief Commercial Officer Jeffrey Del Carmen Sold A Bunch Of Shares In Catalyst Pharmaceuticals - Simply Wall St
Catalyst Pharmaceuticals chief compliance officer sells $1.45 million in stock By Investing.com - Investing.com South Africa
Catalyst Pharmaceuticals chief commercial officer sells $696,382 in stock - Investing.com India
Carmen Del Sells 30,423 Shares of Catalyst Pharmaceuticals Inc (CPRX) - GuruFocus.com
Catalyst Pharmaceuticals chief compliance officer sells $1.45 million in stock - Investing.com
Catalyst Pharmaceuticals chief commercial officer sells $696,382 in stock By Investing.com - Investing.com South Africa
Catalyst Pharmaceuticals Executives Conduct Major Stock Transactions - TradingView
We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Robust Earnings Are Conservative - Yahoo Finance
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference - GlobeNewswire
When and Where to Hear Catalyst Pharmaceuticals' Future Plans: CEO Set for Major Healthcare Conference - StockTitan
Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target Raised to $32.00 at Robert W. Baird - Defense World
Catalyst Pharmaceuticals: Stable Firdapse, Promising Agamree, Fycompa Challenges - Seeking Alpha
Catalyst Pharmaceuticals’ (CPRX) “Buy” Rating Reiterated at HC Wainwright - Defense World
Catalyst Pharmaceuticals (NASDAQ:CPRX) Raised to Strong-Buy at StockNews.com - Defense World
Sanctuary Advisors LLC Has $1.24 Million Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates - MSN
Catalyst Pharmaceuticals Inc (CPRX) Q4 2024 Earnings Call Highli - GuruFocus.com
Catalyst Pharmaceuticals (NASDAQ:CPRX) Shares Gap UpHere's What Happened - MarketBeat
Catalyst Pharmaceuticals' (CPRX) "Overweight" Rating Reaffirmed at Stephens - MarketBeat
Oppenheimer Adjusts Price Target on Catalyst Pharmaceuticals to $32 From $31, Maintains Outperform Rating - Marketscreener.com
Ieq Capital LLC Invests $313,000 in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Principal Financial Group Inc. Grows Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Earnings call transcript: Catalyst Pharmaceuticals Q4 2024 beats expectations By Investing.com - Investing.com Australia
Catalyst Pharmaceuticals Inc (CPRX) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Catalyst Pharmaceuticals Reports Record 2024 Financial Results - TipRanks
Catalyst Pharmaceuticals Reports Strong Growth Amid Challenges - TipRanks
Catalyst Pharmaceuticals (NASDAQ:CPRX) Announces Quarterly Earnings Results - MarketBeat
Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today - MSN
Catalyst Pharmaceuticals Inc (CPRX) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Catalyst Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
Catalyst Pharmaceuticals Inc Azioni (CPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.46%
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):